PYC Therapeutics（PYC）株式概要PYCセラピューティクス社は医薬品開発会社で、オーストラリアで遺伝性疾患治療のための新規RNA治療薬の発見と開発に従事している。 詳細PYC ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るPYC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$1.36該当なし内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-48m25m2016201920222025202620282031Revenue -AU$73.9kEarnings -AU$13.4kAdvancedSet Fair ValueView all narrativesPYC Therapeutics Limited 競合他社Clinuvel PharmaceuticalsSymbol: ASX:CUVMarket cap: AU$458.9mRacura OncologySymbol: ASX:RACMarket cap: AU$464.0mTetratherixSymbol: ASX:TTXMarket cap: AU$352.3mAroa BiosurgerySymbol: ASX:ARXMarket cap: AU$216.2m価格と性能株価の高値、安値、推移の概要PYC Therapeutics過去の株価現在の株価AU$1.3652週高値AU$1.7652週安値AU$0.85ベータ1.051ヶ月の変化5.43%3ヶ月変化-9.33%1年変化13.33%3年間の変化147.27%5年間の変化-12.26%IPOからの変化444.00%最新ニュースBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listingお知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listingお知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct ListingBoard Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listingお知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listingお知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct ListingBoard Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 18PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australiaお知らせ • Sep 22Pyc Therapeutics Limited Announces Board ChangesPYC Therapeutics Limited announced appointment of Professor Ian Jeffrey Constable effective 21 September 2025. cessation of Dr Rohan Hockings effective 16 September 2025, MICHAEL ROSENBLATT effective 21 September 2025, and JASON HADDOCK effective 21 September 2025 as Director.お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.Board Change • Aug 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board Marc Pennesi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Breakeven Date Change • Aug 18Forecast to breakeven in 2028The 5 analysts covering PYC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$129.9m in 2028. Average annual earnings growth of 24% is required to achieve expected profit on schedule.お知らせ • Apr 10PYC Therapeutics Limited Announces First Subject in Phase 1A Single Ascending Dose (Sad) Study of PYC -003PYC Therapeutics Limited announced that the first subject in a Phase 1a Single Ascending Dose (SAD) study of PYC-003 in healthy volunteers has been dosed with the drug candidate. The subject received a 0.4 mg/kg dose of PYC-003 intravenously. Seven additional healthy volunteers will receive either the drug candidate at the same dose or a placebo control over the coming weeks. A meeting of the Safety Review Committee (SRC) overseeing this clinical trial will occur in June/July4 to review the 4-week follow-up data from all subjects in this cohort and an anticipated request to escalate dosing in cohort 2 of the SAD to 1.2 mg/kg5. Part B of this Phase 1a study will evaluate the safety/tolerability and efficacy profile of PYC-003 in patients with PKD - this part of the trial is expected to commence in third quarter 20256. Parts A and B of the SAD will be followed by an Open-Label Extension (OLE) study facilitating repeat dosing and evaluation of the optimal dosing regimen of PYC-003 alongside a Phase 1b Multiple Ascending Dose (MAD) study to evaluate the safety/t tolerability and efficacy profile of PY-003.お知らせ • Feb 18PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 116,651,930 Price\Range: AUD 1.25 Transaction Features: Rights OfferingBoard Change • Feb 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board Marc Pennesi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Dec 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board David Birch was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Nov 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$88.7m (US$57.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (AU$88.7m market cap, or US$57.3m).お知らせ • Oct 14PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia AustraliaBoard Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board David Birch was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 01PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 499,999,999 Price\Range: AUD 0.08 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 168,509,482 Price\Range: AUD 0.08 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,600,000 Price\Range: AUD 0.08 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 194,106,793 Price\Range: AUD 0.08 Transaction Features: Regulation S; Rights OfferingBreakeven Date Change • May 01Forecast to breakeven in 2026The 2 analysts covering PYC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$14.1m in 2026. Average annual earnings growth of 38% is required to achieve expected profit on schedule.お知らせ • Mar 14PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million. Security Name: Ordianry Shares Security Type: Common Stock Securities Offered: 933,216,784 Price\Range: AUD 0.08 Transaction Features: Rights OfferingNew Risk • Nov 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$25m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$25m free cash flow). Earnings are forecast to decline by an average of 6.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$28m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Nov 15Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney DiseasePYC Therapeutics announced the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication. PYC-003 is the fourth program in the Company's development pipeline – joining three other first-in-class RNA drug candidates with disease-modifying potential currently progressing into or through human trials. PYC plans to accelerate PYC-003 into human trials following these results. An Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to enable the commencement of human trials for this drug candidate is planned for H2 2024. PYC-003 is expected to have an accelerated pathway through human trials due to the extent of the unmet patient need in PKD. A New Drug Application in support of this candidate could be submitted following two clinical trials rather than the conventional three. PKD is a monogenic disease (meaning that it is caused by a mutation in a single gene). Drugs targeting monogenic diseases have the highest likelihood of demonstrating efficacy in clinical trials[12] and lower probability of off-target safety issues. PKD affects 1 in every 1,000 people across the globe. There are currently no drugs available that address the underlying cause of the disease and approximately 50% of PKD patients will progress to end-stage renal failure by the age of 60. PKD is characterised by the formation of multiple fluid filled cysts throughout the kidney and, to a lesser extent, other organs. Progression of the cyst frequency and volume over time ultimately leads to destruction of the internal architecture and function of the kidney. The data demonstrating that PYC-003 is effective in 3D patient-derived cyst models complements existing data from animal models highlighting the ability of this drug candidate to reach the cells affected in PKD[14]. PYC's drug delivery platform has already demonstrated the ability to deliver an RNA therapy to the target cells affected by the disease in vivo in high concentration.お知らせ • Oct 24PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023, at 09:00 W. Australia Standard Time. Location: The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands Western Australia Australia Agenda: To consider annual report; to consider remuneration report; to consider re-Election of Dr Michael Rosenblatt; to consider re Approval of Long Term Incentive Plan; and to consider re-insertion of proportional takeover provisions.New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$26m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$21m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Aug 12PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development ProgramPYC Therapeutics Limited announced that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA). The Fast Track process is "designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need" with Fast Track status " often leading to earlier drug approval and access by patients". Benefits of the Fast Track designation include: Increased frequency of meetings with the FDA to discuss the drug's development plan; Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met; and The potential for a Rolling Review in support of a New Drug Application. PYC will utilise the Fast Track designation to work with the FDA on advancing this important drug program towards patients on an accelerated timeline.Recent Insider Transactions • Jun 29Non-Executive Chair of the Board recently bought AU$85k worth of stockOn the 26th of June, Alan Tribe bought around 2m shares on-market at roughly AU$0.053 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Alan has been a buyer over the last 12 months, purchasing a net total of AU$219k worth in shares.お知らせ • Jun 01Pyc Appoints Andrew Taylor as Joint Company SecretaryPYC advises the appointment of the company's Chief Financial Officer Mr. Andrew Taylor as joint Company Secretary effective immediately. Andrew is a chartered accountant and holds a Bachelor of Commerce degree from theUniversity of Western Australia and a Graduate Diploma of Applied Finance. He has over 13 years' experience in big 4 and ASX listed companies with international operations.お知らせ • Feb 03PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug AdministrationPYC Therapeutics Limited announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) in support of its lead drug candidate known as VP-001. The FDA has a period of 30 days to review an IND application. In the event the IND is accepted, VP-001 will be the first investigational drug candidate with the potential to modify the course of Retinitis Pigmentosa type 11 to progress into clinical trials.Board Change • Nov 17High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Judy Lieberman is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Aug 09Non-Executive Chair of the Board recently bought AU$103k worth of stockOn the 3rd of August, Alan Tribe bought around 2m shares on-market at roughly AU$0.061 per share. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Judy Lieberman is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Feb 20Non-Executive Chair of the Board recently bought AU$81k worth of stockOn the 17th of February, Alan Tribe bought around 600k shares on-market at roughly AU$0.14 per share. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.株主還元PYCAU BiotechsAU 市場7D-4.6%0.6%0.08%1Y13.3%-55.8%3.1%株主還元を見る業界別リターン: PYC過去 1 年間で-55.8 % の収益を上げたAustralian Biotechs業界を上回りました。リターン対市場: PYC過去 1 年間で3.1 % の収益を上げたAustralian市場を上回りました。価格変動Is PYC's price volatile compared to industry and market?PYC volatilityPYC Average Weekly Movement7.5%Biotechs Industry Average Movement11.0%Market Average Movement10.5%10% most volatile stocks in AU Market17.5%10% least volatile stocks in AU Market4.3%安定した株価: PYC 、 Australian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: PYCの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001n/aRohan Hockingspyctx.comPYC Therapeutics Limitedは医薬品開発会社で、オーストラリアで遺伝性疾患治療のための新規RNA治療薬の発見と開発に従事している。同社は、11型網膜色素変性症の治療薬として第1相臨床試験を実施中のVP-001、失明の恐れのある眼疾患の治療薬候補であるPYC-001、重度の神経発達障害の治療薬候補であるPYC-002、常染色体優性多発性嚢胞腎の治療薬であるPYC-003を提供している。PYCセラピューティクス・リミテッドはマードック大学と産学共同研究を行っており、神経変性疾患分野における創薬・開発活動を支援している。同社は以前Phylogica Limitedとして知られていたが、2019年11月にPYC Therapeutics Limitedに社名を変更した。PYC Therapeutics Limitedは2001年に法人化され、オーストラリアのネッドランズを拠点としている。もっと見るPYC Therapeutics Limited 基礎のまとめPYC Therapeutics の収益と売上を時価総額と比較するとどうか。PYC 基礎統計学時価総額AU$1.34b収益（TTM）-AU$47.56m売上高(TTM)AU$20.56m65.1xP/Sレシオ-28.1xPER（株価収益率PYC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PYC 損益計算書（TTM）収益AU$20.56m売上原価AU$0売上総利益AU$20.56mその他の費用AU$68.12m収益-AU$47.56m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.048グロス・マージン100.00%純利益率-231.33%有利子負債／自己資本比率0%PYC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 03:29終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PYC Therapeutics Limited 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Melissa BensonBarrenjoey Markets Pty LimitedThomas WakimBell PotterDavid MartinBloom Burton & Co.3 その他のアナリストを表示
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listing
お知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listing
お知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 18PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australia
お知らせ • Sep 22Pyc Therapeutics Limited Announces Board ChangesPYC Therapeutics Limited announced appointment of Professor Ian Jeffrey Constable effective 21 September 2025. cessation of Dr Rohan Hockings effective 16 September 2025, MICHAEL ROSENBLATT effective 21 September 2025, and JASON HADDOCK effective 21 September 2025 as Director.
お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Board Change • Aug 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board Marc Pennesi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Breakeven Date Change • Aug 18Forecast to breakeven in 2028The 5 analysts covering PYC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$129.9m in 2028. Average annual earnings growth of 24% is required to achieve expected profit on schedule.
お知らせ • Apr 10PYC Therapeutics Limited Announces First Subject in Phase 1A Single Ascending Dose (Sad) Study of PYC -003PYC Therapeutics Limited announced that the first subject in a Phase 1a Single Ascending Dose (SAD) study of PYC-003 in healthy volunteers has been dosed with the drug candidate. The subject received a 0.4 mg/kg dose of PYC-003 intravenously. Seven additional healthy volunteers will receive either the drug candidate at the same dose or a placebo control over the coming weeks. A meeting of the Safety Review Committee (SRC) overseeing this clinical trial will occur in June/July4 to review the 4-week follow-up data from all subjects in this cohort and an anticipated request to escalate dosing in cohort 2 of the SAD to 1.2 mg/kg5. Part B of this Phase 1a study will evaluate the safety/tolerability and efficacy profile of PYC-003 in patients with PKD - this part of the trial is expected to commence in third quarter 20256. Parts A and B of the SAD will be followed by an Open-Label Extension (OLE) study facilitating repeat dosing and evaluation of the optimal dosing regimen of PYC-003 alongside a Phase 1b Multiple Ascending Dose (MAD) study to evaluate the safety/t tolerability and efficacy profile of PY-003.
お知らせ • Feb 18PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 116,651,930 Price\Range: AUD 1.25 Transaction Features: Rights Offering
Board Change • Feb 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board Marc Pennesi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Dec 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board David Birch was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Nov 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$88.7m (US$57.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (AU$88.7m market cap, or US$57.3m).
お知らせ • Oct 14PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australia
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board David Birch was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 01PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 499,999,999 Price\Range: AUD 0.08 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 168,509,482 Price\Range: AUD 0.08 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,600,000 Price\Range: AUD 0.08 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 194,106,793 Price\Range: AUD 0.08 Transaction Features: Regulation S; Rights Offering
Breakeven Date Change • May 01Forecast to breakeven in 2026The 2 analysts covering PYC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$14.1m in 2026. Average annual earnings growth of 38% is required to achieve expected profit on schedule.
お知らせ • Mar 14PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million. Security Name: Ordianry Shares Security Type: Common Stock Securities Offered: 933,216,784 Price\Range: AUD 0.08 Transaction Features: Rights Offering
New Risk • Nov 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$25m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$25m free cash flow). Earnings are forecast to decline by an average of 6.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$28m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Nov 15Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney DiseasePYC Therapeutics announced the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication. PYC-003 is the fourth program in the Company's development pipeline – joining three other first-in-class RNA drug candidates with disease-modifying potential currently progressing into or through human trials. PYC plans to accelerate PYC-003 into human trials following these results. An Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to enable the commencement of human trials for this drug candidate is planned for H2 2024. PYC-003 is expected to have an accelerated pathway through human trials due to the extent of the unmet patient need in PKD. A New Drug Application in support of this candidate could be submitted following two clinical trials rather than the conventional three. PKD is a monogenic disease (meaning that it is caused by a mutation in a single gene). Drugs targeting monogenic diseases have the highest likelihood of demonstrating efficacy in clinical trials[12] and lower probability of off-target safety issues. PKD affects 1 in every 1,000 people across the globe. There are currently no drugs available that address the underlying cause of the disease and approximately 50% of PKD patients will progress to end-stage renal failure by the age of 60. PKD is characterised by the formation of multiple fluid filled cysts throughout the kidney and, to a lesser extent, other organs. Progression of the cyst frequency and volume over time ultimately leads to destruction of the internal architecture and function of the kidney. The data demonstrating that PYC-003 is effective in 3D patient-derived cyst models complements existing data from animal models highlighting the ability of this drug candidate to reach the cells affected in PKD[14]. PYC's drug delivery platform has already demonstrated the ability to deliver an RNA therapy to the target cells affected by the disease in vivo in high concentration.
お知らせ • Oct 24PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023, at 09:00 W. Australia Standard Time. Location: The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands Western Australia Australia Agenda: To consider annual report; to consider remuneration report; to consider re-Election of Dr Michael Rosenblatt; to consider re Approval of Long Term Incentive Plan; and to consider re-insertion of proportional takeover provisions.
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$26m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$21m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Aug 12PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development ProgramPYC Therapeutics Limited announced that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA). The Fast Track process is "designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need" with Fast Track status " often leading to earlier drug approval and access by patients". Benefits of the Fast Track designation include: Increased frequency of meetings with the FDA to discuss the drug's development plan; Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met; and The potential for a Rolling Review in support of a New Drug Application. PYC will utilise the Fast Track designation to work with the FDA on advancing this important drug program towards patients on an accelerated timeline.
Recent Insider Transactions • Jun 29Non-Executive Chair of the Board recently bought AU$85k worth of stockOn the 26th of June, Alan Tribe bought around 2m shares on-market at roughly AU$0.053 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Alan has been a buyer over the last 12 months, purchasing a net total of AU$219k worth in shares.
お知らせ • Jun 01Pyc Appoints Andrew Taylor as Joint Company SecretaryPYC advises the appointment of the company's Chief Financial Officer Mr. Andrew Taylor as joint Company Secretary effective immediately. Andrew is a chartered accountant and holds a Bachelor of Commerce degree from theUniversity of Western Australia and a Graduate Diploma of Applied Finance. He has over 13 years' experience in big 4 and ASX listed companies with international operations.
お知らせ • Feb 03PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug AdministrationPYC Therapeutics Limited announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) in support of its lead drug candidate known as VP-001. The FDA has a period of 30 days to review an IND application. In the event the IND is accepted, VP-001 will be the first investigational drug candidate with the potential to modify the course of Retinitis Pigmentosa type 11 to progress into clinical trials.
Board Change • Nov 17High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Judy Lieberman is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Aug 09Non-Executive Chair of the Board recently bought AU$103k worth of stockOn the 3rd of August, Alan Tribe bought around 2m shares on-market at roughly AU$0.061 per share. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Judy Lieberman is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Feb 20Non-Executive Chair of the Board recently bought AU$81k worth of stockOn the 17th of February, Alan Tribe bought around 600k shares on-market at roughly AU$0.14 per share. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.
